Product
nal-IRI
2 clinical trials
4 indications
Indication
Pancreatic CancerIndication
Gastric AdenocarcinomaIndication
Second LineIndication
ChemotherapyClinical trial
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2021-02-15
Clinical trial
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).Status: Not yet recruiting, Estimated PCD: 2025-08-31